Vaxcyte Doses First Participants In Phase 1/2 Clinical Study Evaluating VAX-24 For Prevention Of Invasive Pneumococcal Disease And Pneumonia In Adults
-- Company Expects to Announce Topline Results from the Phase 1/2 Study by the End of 2022 --
-- Proof-of-Concept Study Will Evaluate the Safety, Tolerability and Immunogenicity of VAX-24 --
-- VAX-24 is a